Ocugen (OCGN) Scheduled to Post Quarterly Earnings on Friday


Share on StockTwits

Ocugen (NASDAQ:OCGN) is scheduled to be announcing its earnings results before the market opens on Friday, May 7th. Analysts expect the company to announce earnings of $0.50 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings data on Wednesday, March 17th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.04. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ:OCGN traded down $2.91 on Tuesday, reaching $12.77. The stock had a trading volume of 1,226,875 shares, compared to its average volume of 72,234,508. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 0.13. Ocugen has a 12-month low of $0.17 and a 12-month high of $18.77. The company has a 50-day moving average of $8.12 and a 200 day moving average of $4.42. The stock has a market cap of $2.40 billion, a P/E ratio of -8.28 and a beta of 3.56.

In other news, SVP Vijay Tammara sold 29,991 shares of Ocugen stock in a transaction dated Thursday, April 29th. The shares were sold at an average price of $10.97, for a total transaction of $329,001.27. Following the sale, the senior vice president now directly owns 9,000 shares in the company, valued at approximately $98,730. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ramesh Kumar sold 7,500 shares of Ocugen stock in a transaction dated Monday, April 19th. The shares were sold at an average price of $5.33, for a total transaction of $39,975.00. Following the sale, the director now owns 7,500 shares in the company, valued at $39,975. The disclosure for this sale can be found here. Insiders sold a total of 665,607 shares of company stock worth $8,390,799 over the last 90 days. Company insiders own 3.54% of the company’s stock.

Several equities analysts have recently commented on OCGN shares. Roth Capital increased their price target on shares of Ocugen from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. Chardan Capital cut shares of Ocugen from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 9th. HC Wainwright raised shares of Ocugen from a “neutral” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Thursday, February 4th. Zacks Investment Research lowered shares of Ocugen from a “buy” rating to a “hold” rating in a research note on Thursday, February 11th. Finally, Cantor Fitzgerald increased their price objective on shares of Ocugen from $1.00 to $4.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 3rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $5.04.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.

Featured Story: Stock Selection – What is cash flow?

Earnings History for Ocugen (NASDAQ:OCGN)

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.